|
|
Post by mannmade on Oct 2, 2018 20:06:25 GMT -5
www.yahoo.com/news/eli-lillys-diabetes-treatment-meets-main-goal-two-103258999--finance.htmlEli Lilly's diabetes treatment meets main goal in two late-stage studies Reuters Reuters 14 hours ago (Reuters) - Eli Lilly and Co said on Tuesday its experimental diabetes treatment was shown to be as effective as the drugmaker's Humalog medicine in two late-stage studies. The study also found that the drug, Ultra Rapid Lispro, significantly improved post-meal blood sugar levels in people with both type 1 and type 2 diabetes and had a similar safety profile as Humalog. Ultra Rapid Lispro is a mealtime insulin formulation being developed to help better control blood glucose levels after meals by more closely mirroring the way insulin works in people without diabetes. Lilly has an large diabetes franchise including Trulicity, Humalog and Humulin. Its bestselling Humalog brought in revenue of $769.8 million in the last quarter. About 30 million Americans suffer from diabetes, of which an estimated 90 to 95 percent have type 2 diabetes.
|
|
|
|
Post by sayhey24 on Oct 2, 2018 20:22:41 GMT -5
Maybe Dr. Kendall can call his old friends and tell them to stop wasting their money and just buy MNKD for $100pps
|
|
|
|
Post by ltta on Oct 2, 2018 20:29:08 GMT -5
"Ultra Rapid Lispro"? What the heck? What is "Ultra"? What is Afrezza?
|
|
|
|
Post by sayhey24 on Oct 2, 2018 20:39:50 GMT -5
Mike said today they are working with a third party (maybe the ADA?) to get the "Ultra" category. If afrezza is the first then others would have to show non-inferiority to afrezza in speed to also be in the "Ultra" category.
As I said, Lilly should save their money and just buy MNKD.
|
|
|
|
Post by mnkdfann on Oct 2, 2018 20:54:47 GMT -5
Mike said today they are working with a third party (maybe the ADA?) to get the "Ultra" category. If afrezza is the first then others would have to show non-inferiority to afrezza in speed to also be in the "Ultra" category. I have serious doubts that the ADA would be involved. My money would be on Vdex being the third party. |
|
|
|
Post by agedhippie on Oct 3, 2018 18:28:51 GMT -5
Mike said today they are working with a third party (maybe the ADA?) to get the "Ultra" category. If afrezza is the first then others would have to show non-inferiority to afrezza in speed to also be in the "Ultra" category. I have serious doubts that the ADA would be involved. My money would be on Vdex being the third party. My money is it being Novo Nordisk and Lilly. A nice new shiny class name to help them sell their new insulins would be very useful. |
|
|
|
Post by mannmade on Oct 3, 2018 19:06:15 GMT -5
It would also help them justify pricing...
|
|
|
|
Post by sayhey24 on Oct 3, 2018 19:06:27 GMT -5
Aged - the new class would have to be established by an industry neutral "third party". The only one in the diabetes space which comes to mind which defines classes and standards of care is the ADA.
Can you think of another?
|
|
|
|
Post by sayhey24 on Oct 3, 2018 19:40:56 GMT -5
Here is Mike said "So we do have a unique insulin, we are working with third parties to try to get a new classification of ultra-acting. We'll continue to focus on that."
My guess is the AACE is the other as Mike said "parties".
|
|
|
|
Post by compound26 on Oct 3, 2018 20:26:18 GMT -5
Here is Mike said "So we do have a unique insulin, we are working with third parties to try to get a new classification of ultra-acting. We'll continue to focus on that." My guess is the AACE is the other as Mike said "parties". Agree. ADA is most likely a party. JDRF could also be such a party. |
|
|
|
Post by agedhippie on Oct 4, 2018 8:21:53 GMT -5
It would also help them justify pricing... Indeed. The price of Fiasp is the same as the price of Novolog, the same as Sanofi did with Lantus and Toujeo. I think it's about moving people off a patent expired drug to a new one before the biosimilars commoditize the market and undercut the price for the old RAA. |
|
|
|
Post by agedhippie on Oct 4, 2018 8:26:12 GMT -5
Aged - the new class would have to be established by an industry neutral "third party". The only one in the diabetes space which comes to mind which defines classes and standards of care is the ADA. Can you think of another? FDA. They control the descriptions and claims for drugs. If they have any sense they will avoid the ultra-rapid designation because what comes next, ultra ultra rapid? There is already confusion between fast acting (Regular insulin), and rapid acting (RAA) as to which is faster based on the name. |
|
|
|
Post by agedhippie on Oct 4, 2018 8:27:11 GMT -5
To get back to the original post - note that the Lilly insulin is non-inferior and not superior to Humalog.
|
|
|
|
Post by goyocafe on Oct 4, 2018 9:04:01 GMT -5
Aged - the new class would have to be established by an industry neutral "third party". The only one in the diabetes space which comes to mind which defines classes and standards of care is the ADA. Can you think of another? FDA. They control the descriptions and claims for drugs. If they have any sense they will avoid the ultra-rapid designation because what comes next, ultra ultra rapid? There is already confusion between fast acting (Regular insulin), and rapid acting (RAA) as to which is faster based on the name. Maybe they need to introduce a speed rating system like they do for tires. L 75 mph 120 km/h Off-Road & Light Truck Tires M 81 mph 130 km/h Temporary Spare Tires N 87 mph 140km/h P 93 mph 150 km/h Q 99 mph 160 km/h Studless & Studdable Winter Tires R 106 mph 170 km/h H.D. Light Truck Tires S 112 mph 180 km/h Family Sedans & Vans T 118 mph 190 km/h Family Sedans & Vans U 124 mph 200 km/h H 130 mph 210 km/h Sport Sedans & Coupes V 149 mph 240 km/h Sport Sedans, Coupes & Sports Cars W 168 mph 270 km/h Exotic Sports Cars Y 186 mph 300 km/h Exotic Sports Cars That ought to simplify it! 🙄 |
|
|
|
Post by mango on Oct 4, 2018 11:39:38 GMT -5
RAAs aren't even insulin. No wonder people are confused
|
|
